Navigation Links
Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
Date:2/12/2009

IB1001, an Intravenous Recombinant Factor IX (rFIX) Product for the Treatment of Hemophilia B

LAGUNA NIGUEL, Calif., Feb. 12 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc., today announced the initiation of a Phase 1 clinical trial of IB1001, an intravenous (IV) recombinant Factor IX (rFIX) product for control and prevention of hemorrhagic episodes in patients with hemophilia B. It is estimated that the market for therapies to treat this disorder is in excess of $600 million.

The Phase 1 clinical trial is designed to assess the safety, tolerability and pharmacokinetics of IB1001 in patients with hemophilia B, compared with the commercially available rFIX product. Following the successful completion of this study, patients will then be followed for the six month Phase 2/3 trial either based on an on-demand or prophylaxis protocol.

"The initiation of this Phase 1 trial is an important milestone for the Company and for the hemophilia community," said John Taylor, Chairman and Co-founder, Inspiration Biopharmaceuticals. "This is the first therapy for hemophilia B patients in the past two decades. We continue to develop a Factor product portfolio in both IV and non-invasive dosage forms for hemophilia and other coagulation disorders."

About IB1001

IB1001 is an intravenous recombinant Factor IX product for the acute and preventative treatment of the bleeding disorder associated with hemophilia B. IB1001 is produced with Inspiration's proprietary recombinant protein manufacturing technology, which significantly increases cell-line productivity.

About Hemophilia

Hemophilia is a lifelong, inherited bleeding disorder caused by low levels or absence of a protein called a clotting factor, essential for blood clotting. This inability to clot results from an error in a person's genetic code, and occurs in approximately 1 in 10,000 male births.
'/>"/>

SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
2. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
3. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
5. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Meritage Pharma Initiates Phase 2b Clinical Trial of Oral Viscous Budesonide for Pediatric Patients With Eosinophilic Esophagitis
8. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
9. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
10. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
11. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... /PRNewswire-iReach/ -- TwinMed, LLC announced today that ... H.Eric Richard, Inc. (collectively "PrimeCare"), a New England based ... Massachusetts and Maine. "This acquisition is ... substantially increase our base of service for Long Term ...
... flu season still active and allergy season on its ... to actively seek their pharmacist,s advice about the proper ... care provider and are available to help the public ... and allergy symptoms. (Logo: http://photos.prnewswire.com/prnh/20100820/APHALOGO-a ) ...
Cached Medicine Technology:Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 2Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 3Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists 4
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... genetic variant specifically associated with the risk of ... per cent of all breast cancer cases. , ... sub-type, called invasive lobular carcinoma, gives researchers important ... kind of breast cancer, which can be missed ... in the journal PloS Genetics , was ...
(Date:4/17/2014)... the April issue of Experimental Biology and ... Drs. Rex Gaskins and Paul Kenis in the ... of the University of Illinois Urbana-Champaign describe their ... reactions underlie a variety of cell functions including ... these crucial roles in regulating normal cellular behavior, ...
(Date:4/17/2014)... Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was ... April issue of Nature Reviews Microbiology , ... Dr. McCullers, a world-renowned infectious disease specialist, and ... University of Tennessee Health Science Center, analyzed the ... 1957 and 1968 pandemics, as well as more ...
(Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2
... Aug. 19 Lupin Ltd.,announced today that the Company ... the AeroChamber Plus(R) line of products with,Forest Laboratories, Inc. ... will use its 50 person sales force to promote,the ... Holding Chamber (VHC) device that is,used with metered dose ...
... Private Access Appoints Marc Kirshbaum as President & COO, Former ... Medical Research through its suite of web-based privacy management ... clinical ... Private Access,Inc., a developer of web-based solutions that enable management ...
... LINTHICUM, MD, August 18, 2008Young researchers presented innovative, ... Conference, a collaborative project of the AUA Foundation ... on August 7-9, 2008. The AUA Foundation hosted ... discuss the most cutting-edge research in sexual medicine. ...
... Team Conference on October 23,2008, ALEXANDRIA, Va., ... improving America,s future. A strong advocate for,children and ... advocate and,tireless worker on behalf of important social ... Edwards will be the opening speaker at,the National ...
... Cialis showed benefit without side effects , , TUESDAY, ... the erectile dysfunction drug tadalafil (Cialis) helped relieve lower ... prostates, according to a new study. , More than ... lower urinary tract symptoms, including increased urination frequency and ...
... more wide-spread ... authentication for network access, DALLAS, Aug. 19 To ... two-factor authentication via hardware tokens in order to,protect patient files, ... to deploy to a wider audience and,cumbersome for the medical ...
Cached Medicine News:Health News:Lupin Enters into a Marketing Alliance with Forest Laboratories, Inc. for AeroChamber Plus(R) Brand in the US - Extends its Franchise with Pediatricians 2Health News:VirtualHealth Technologies, Inc., Announces Its Associate, Private Access, Appoints Marc Kirshbaum as President & COO 2Health News:VirtualHealth Technologies, Inc., Announces Its Associate, Private Access, Appoints Marc Kirshbaum as President & COO 3Health News:New research on sexual function 2Health News:Elizabeth Edwards to be Opening Speaker at National Hospice Conference in Dallas 2Health News:ED Drug Relieves Lower Urinary Tract Symptoms 2Health News:Entrust IdentityGuard Enables Georgia-based Hospital Network to Deploy Strong Authentication for Remote Access 2Health News:Entrust IdentityGuard Enables Georgia-based Hospital Network to Deploy Strong Authentication for Remote Access 3
... An ISI technician carefully inspects your equipment ... any and all problems, and provides you with ... may be working within a tight budget so ... the intricate work of repair begins., , ISI ...
... ALT (GPT) powder reagent is intended for ... in serum. , Infinity ALT (GPT) powder ... stability once reconstituted and convenience, but ensures ... The reagent is suitable for manual use ...
... is a fully automated, versatile analyzer ... is increased due to the continuous loading ... A fully graphical user interface provides fast ... use. Konelab analyzers are delivered with full ...
Inquire...
Medicine Products: